STE

Business profile & competitive position

STERIS plc operates in the Healthcare sector, specifically the Medical - Specialties industry. It is a global provider of infection-prevention and patient-care products and services, organized into three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its offerings include consumables such as detergents, endoscopy accessories, instruments, and barrier products; capital equipment such as sterilizers, surgical tables, and automated endoscope reprocessors; and services that include equipment installation and maintenance, instrument and scope repair, laboratory testing, microbial reduction, outsourced reprocessing, and operating-room connectivity solutions. Following the fiscal 2025 divestiture of the Dental segment, that business is now reported as discontinued operations.

The company’s reported trailing financials provide a concrete view of its competitive position. A net margin of 13.3% and a return on equity of 11.3% point to solid, repeatable profitability but not an unusually wide moat. Those figures are consistent with a business built on a large installed base of capital equipment that generates recurring revenue from consumables, maintenance, and service contracts. Supporting that steadiness, STERIS reported that no single customer represented more than 10% of segment revenue in Healthcare, AST, or Life Sciences for fiscal 2026. It also reported zero FDA or other regulatory enforcement actions, zero products in the FDA MedWatch Safety Alerts database, and no Class I recalls in fiscal 2026, 2025, or 2024.

Financial posture

STERIS currently carries a market capitalization of $23.2 billion, trades at a P/E ratio of 29.0, and has a beta of 0.91. The stock is quoted at $237.87, with a 50-day exponential moving average of $225.19 and an RSI of 61.7. A P/E of 29.0 sits at a premium to the broader market and reflects the Healthcare/Medical - Specialties premium typically applied to businesses with durable revenue streams. Against that, the 13.3% net margin and 11.3% ROE provide fundamental support for the multiple, though they do not make the stock look obviously cheap on a pure profitability basis.

The 0.91 beta tells investors that the shares have historically moved slightly less than the overall market, which fits the defensive, non-cyclical character of infection-prevention and sterilization demand. The gap between the current price and the 50-day EMA—about $12.68—shows the stock has recently been stronger than its medium-term trend, while the RSI below 70 still leaves it short of traditional overbought territory. Taken together, the numbers describe a higher-quality healthcare name priced for continued steady growth.

Strategic priorities & outlook

STERIS’s most recent 10-K filing outlines a set of operational priorities that center on capacity expansion, operational efficiency, disciplined M&S, and ESG readiness. First, the company plans to continue expanding irradiation processing capacity with accelerator-based technologies. That initiative is explicitly aimed at reducing reliance on cobalt-60 supply, an important raw-material consideration for sterilization services.

• Apply Lean and continuous-improvement principles across manufacturing, service operations, back-office functions, and support functions.
• Use acquisitions as a key part of the long-term growth strategy.
• Set near-term company-wide emissions reductions and prepare for CSRD/ESRS and TCFD-aligned ESG disclosure requirements.

Operationally, the 10-K also noted that the capital-equipment backlog stood at $490.7 million at March 31, 2026, up from $452.9 million at March 31, 2025. Management attributed the increase to shipment timing and acquisitions. That backlog growth is a concrete, forward-looking metric for the capital-equipment side of the business and aligns with the broader push to expand capacity and scale through both organic investment and bolt-on deals.

Macro & geopolitical exposure

Because STERIS is classified in Healthcare/Medical - Specialties, its exposures are anchored in the structural realities of healthcare delivery rather than broad consumer demand. The industry is heavily regulated by the FDA and comparable agencies overseas, so changes to device approval pathways, quality-system requirements, or sterilization standards can directly affect product and service economics.

Hospital capital-spending cycles are another macro channel. STERIS sells sterilizers, surgical tables, and related capital equipment, so delays or accelerations in hospital construction and upgrade budgets can swing order flow and backlog conversion. The company also faces input-related exposure through isotope and chemical supply chains—notably cobalt-60 and the raw materials behind the $600 million chemistry investment highlighted in recent headlines. Trade policy, tariffs, and currency translation can matter for a global provider of both equipment and consumables. Finally, ESG disclosure requirements in Europe and growing expectations elsewhere add a compliance and reporting layer that the company has already flagged as a near-term priority.

Recent developments

The most recent news flow around STERIS has focused on execution, valuation, and the first-quarter earnings report. On August 21, 2026, zacks.com asked whether the stock can deliver as its $600 million chemistry bet scales. A day earlier, zacks.com ran a piece asking whether investors should buy STERIS as growth meets reasonable valuation. First-quarter earnings-call coverage appeared on defenseworld.net on August 11, 2026, and on marketbeat.com on August 9, 2026. The recurring theme across the headlines is a mix of growth execution and valuation scrutiny, which matches the current P/E of 29.0 and the company’s focus on scaling newer product and service capabilities.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, STERIS has beaten earnings estimates five times, for a beat rate of 71%. The average earnings surprise across those quarters is 2.2%, and the average 5-day price move after earnings is 2.36%, classified as an upward drift.

The four most recent quarters show how varied the short-term reaction can be even when the underlying surprise is modest. On August 5, 2026, STERIS reported EPS of $2.59 against an estimate of $2.49, a 4% positive surprise; the next day the stock fell 0.4%, but it gained 1.67% over the following five days. On May 11, 2026, EPS came in at $2.83 versus $2.85, a 0.7% miss; nevertheless, the stock rose 4.46% the next day and 5.46% over the next five sessions. On February 4, 2026, the company reported $2.53, exactly matching the estimate, and the shares dropped 7.74% the next day and 7.87% over five days. The preceding quarter, November 5, 2025, saw EPS of $2.47 beat the $2.35 estimate by 5.1%, driving a 6.94% next-day gain and a 10.2% five-day gain.

The next scheduled report is November 4, 2026, after the close, with a consensus EPS estimate of $2.68. The historical pattern suggests STERIS has a tendency to deliver modest positive surprises, but the post-earnings price path does not always follow the headline beat or miss. For a deeper dive, including the latest analyst ratings, price targets, and institutional positioning, see the full institutional verdict on the platform.